Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised the Port of Gothenburg in conjunction with the transfer of the car terminal
Mandate

Vinge advised the Port of Gothenburg in conjunction with the transfer of the car terminal

February 17, 2011

As a part of the ongoing privatisation of the terminal operations in the Port of Gothenburg, the car terminal has been transferred to Logent AB. At the same time, a 10-year licence agreement has been entered into between the parties regarding utilisation of the terminal and related infrastructure. The Port of Gothenburg is the largest port in the Nordic region and a focal point for the Swedish car industry. Logent AB is a Swedish company with approximately 1000 employees which conducts ports, combined terminals and warehousing operations in Sweden and Norway. Vinge advised the Port of Gothenburg Harbour during the privatisation procedure.
Vinge’s team consisted of, among others, Fredrik Sonander, Charlotte Johansson and Lisa Askbrink.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024